Is PYXS or CRVO more profitable?

Pyxis Oncology has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Pyxis Oncology's return on equity of -135.60% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -135.60% -85.00% CervoMed -672.80% -136.08% -112.62%

Does the media refer more to PYXS or CRVO?

In the previous week, Pyxis Oncology had 3 more articles in the media than CervoMed. MarketBeat recorded 5 mentions for Pyxis Oncology and 2 mentions for CervoMed. CervoMed's average media sentiment score of 0.93 beat Pyxis Oncology's score of 0.62 indicating that CervoMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CervoMed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRVO or NRXP?

In the previous week, NRx Pharmaceuticals had 3 more articles in the media than CervoMed. MarketBeat recorded 5 mentions for NRx Pharmaceuticals and 2 mentions for CervoMed. CervoMed's average media sentiment score of 0.93 beat NRx Pharmaceuticals' score of 0.31 indicating that CervoMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CervoMed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NRx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IFRX or CRVO more profitable?

InflaRx has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. InflaRx's return on equity of -88.30% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -88.30% -65.77% CervoMed -672.80% -136.08% -112.62%

Does the media favor IFRX or CRVO?

In the previous week, InflaRx and InflaRx both had 2 articles in the media. InflaRx's average media sentiment score of 1.89 beat CervoMed's score of 0.93 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CervoMed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, VTVT or CRVO?

vTv Therapeutics is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio vTv Therapeutics $1.02M 146.59 -$26.97M -$0.93 N/A CervoMed N/A N/A -$26.97M -$3.28 N/A

Is VTVT or CRVO more profitable?

vTv Therapeutics has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. vTv Therapeutics' return on equity of 3.96% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets vTv Therapeutics N/A 3.96% 2.86% CervoMed -672.80% -136.08% -112.62%

Does the media favor VTVT or CRVO?

In the previous week, vTv Therapeutics had 2 more articles in the media than CervoMed. MarketBeat recorded 4 mentions for vTv Therapeutics and 2 mentions for CervoMed. CervoMed's average media sentiment score of 0.93 beat vTv Therapeutics' score of 0.87 indicating that CervoMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment vTv Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CervoMed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate OGI or CRVO?

CervoMed has a consensus price target of $22.60, suggesting a potential upside of 605.37%. Given CervoMed's stronger consensus rating and higher possible upside, analysts plainly believe CervoMed is more favorable than Organigram Global. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram Global 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 CervoMed 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

CervoMed (CRVO) Competitors

$3.20 +0.05 (+1.71%)

As of 02:27 PM Eastern

Compare

CRVO vs. PYXS, NRXP, IFRX, VTVT, and OGI

Should you buy CervoMed stock or one of its competitors? MarketBeat compares CervoMed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CervoMed include Pyxis Oncology (PYXS), NRx Pharmaceuticals (NRXP), InflaRx (IFRX), vTv Therapeutics (VTVT), and Organigram Global (OGI). These companies are all part of the "pharmaceutical products" industry.

How does CervoMed compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Pyxis Oncology currently has a consensus target price of $6.83, indicating a potential upside of 134.42%. CervoMed has a consensus target price of $22.60, indicating a potential upside of 605.37%. Given CervoMed's higher possible upside, analysts plainly believe CervoMed is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

CervoMed has lower revenue, but higher earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	13.33	-$79.62M	-$1.31	N/A
CervoMed	N/A	N/A	-$26.97M	-$3.28	N/A

Pyxis Oncology has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, CervoMed has a beta of -0.68, suggesting that its share price is 168% less volatile than the broader market.

In the previous week, Pyxis Oncology had 3 more articles in the media than CervoMed. MarketBeat recorded 5 mentions for Pyxis Oncology and 2 mentions for CervoMed. CervoMed's average media sentiment score of 0.93 beat Pyxis Oncology's score of 0.62 indicating that CervoMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CervoMed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 25.1% of CervoMed shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by insiders. Comparatively, 35.8% of CervoMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Pyxis Oncology has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Pyxis Oncology's return on equity of -135.60% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
CervoMed	-672.80%	-136.08%	-112.62%

Summary

Pyxis Oncology beats CervoMed on 8 of the 13 factors compared between the two stocks.

How does CervoMed compare to NRx Pharmaceuticals?

CervoMed (NASDAQ:CRVO) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

CervoMed has a beta of -0.68, indicating that its share price is 168% less volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market.

CervoMed has higher earnings, but lower revenue than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	N/A	N/A	-$26.97M	-$3.28	N/A
NRx Pharmaceuticals	$2.29M	65.33	-$28.62M	-$1.09	N/A

In the previous week, NRx Pharmaceuticals had 3 more articles in the media than CervoMed. MarketBeat recorded 5 mentions for NRx Pharmaceuticals and 2 mentions for CervoMed. CervoMed's average media sentiment score of 0.93 beat NRx Pharmaceuticals' score of 0.31 indicating that CervoMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NRx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CervoMed presently has a consensus price target of $22.60, indicating a potential upside of 605.37%. NRx Pharmaceuticals has a consensus price target of $38.25, indicating a potential upside of 825.03%. Given NRx Pharmaceuticals' higher probable upside, analysts clearly believe NRx Pharmaceuticals is more favorable than CervoMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

25.1% of CervoMed shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 35.8% of CervoMed shares are held by company insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

NRx Pharmaceuticals has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. NRx Pharmaceuticals' return on equity of 0.00% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-136.08%	-112.62%
NRx Pharmaceuticals	N/A	N/A	-202.92%

Summary

CervoMed beats NRx Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does CervoMed compare to InflaRx?

InflaRx (NASDAQ:IFRX) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

InflaRx has a beta of 2.42, meaning that its share price is 142% more volatile than the broader market. Comparatively, CervoMed has a beta of -0.68, meaning that its share price is 168% less volatile than the broader market.

InflaRx has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. InflaRx's return on equity of -88.30% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-88.30%	-65.77%
CervoMed	-672.80%	-136.08%	-112.62%

InflaRx presently has a consensus price target of $7.00, suggesting a potential upside of 198.51%. CervoMed has a consensus price target of $22.60, suggesting a potential upside of 605.37%. Given CervoMed's higher probable upside, analysts plainly believe CervoMed is more favorable than InflaRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

42.4% of InflaRx shares are held by institutional investors. Comparatively, 25.1% of CervoMed shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Comparatively, 35.8% of CervoMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, InflaRx and InflaRx both had 2 articles in the media. InflaRx's average media sentiment score of 1.89 beat CervoMed's score of 0.93 indicating that InflaRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CervoMed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CervoMed has lower revenue, but higher earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	5,650.67	-$51.63M	-$0.71	N/A
CervoMed	N/A	N/A	-$26.97M	-$3.28	N/A

Summary

InflaRx beats CervoMed on 10 of the 15 factors compared between the two stocks.

How does CervoMed compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

vTv Therapeutics presently has a consensus target price of $55.33, indicating a potential upside of 45.81%. CervoMed has a consensus target price of $22.60, indicating a potential upside of 605.37%. Given CervoMed's higher probable upside, analysts plainly believe CervoMed is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

vTv Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, CervoMed has a beta of -0.68, indicating that its stock price is 168% less volatile than the broader market.

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 25.1% of CervoMed shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by company insiders. Comparatively, 35.8% of CervoMed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, vTv Therapeutics had 2 more articles in the media than CervoMed. MarketBeat recorded 4 mentions for vTv Therapeutics and 2 mentions for CervoMed. CervoMed's average media sentiment score of 0.93 beat vTv Therapeutics' score of 0.87 indicating that CervoMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
vTv Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CervoMed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

vTv Therapeutics has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. vTv Therapeutics' return on equity of 3.96% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	3.96%	2.86%
CervoMed	-672.80%	-136.08%	-112.62%

vTv Therapeutics is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	146.59	-$26.97M	-$0.93	N/A
CervoMed	N/A	N/A	-$26.97M	-$3.28	N/A

Summary

vTv Therapeutics beats CervoMed on 7 of the 12 factors compared between the two stocks.

How does CervoMed compare to Organigram Global?

Organigram Global (NASDAQ:OGI) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

CervoMed has a consensus price target of $22.60, suggesting a potential upside of 605.37%. Given CervoMed's stronger consensus rating and higher possible upside, analysts plainly believe CervoMed is more favorable than Organigram Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram Global	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Organigram Global has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Comparatively, CervoMed has a beta of -0.68, indicating that its stock price is 168% less volatile than the broader market.

34.6% of Organigram Global shares are held by institutional investors. Comparatively, 25.1% of CervoMed shares are held by institutional investors. 0.1% of Organigram Global shares are held by insiders. Comparatively, 35.8% of CervoMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, CervoMed had 1 more articles in the media than Organigram Global. MarketBeat recorded 2 mentions for CervoMed and 1 mentions for Organigram Global. Organigram Global's average media sentiment score of 1.89 beat CervoMed's score of 0.93 indicating that Organigram Global is being referred to more favorably in the media.

Company	Overall Sentiment
Organigram Global	Very Positive
CervoMed	Positive

Organigram Global has a net margin of -9.22% compared to CervoMed's net margin of -672.80%. Organigram Global's return on equity of -13.41% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram Global	-9.22%	-13.41%	-9.09%
CervoMed	-672.80%	-136.08%	-112.62%

Organigram Global has higher revenue and earnings than CervoMed. Organigram Global is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram Global	$185.07M	0.77	-$17.70M	-$0.13	N/A
CervoMed	N/A	N/A	-$26.97M	-$3.28	N/A

Summary

Organigram Global beats CervoMed on 9 of the 15 factors compared between the two stocks.

Get CervoMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRVO vs. The Competition

Export

Metric	CervoMed	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$35.28M	$3.65B	$6.78B	$12.58B
Dividend Yield	N/A	2.21%	2.66%	6.21%
P/E Ratio	-0.98	21.25	27.32	24.86
Price / Sales	N/A	340.58	561.22	117.20
Price / Cash	N/A	62.10	29.14	36.96
Price / Book	1.63	8.81	11.08	6.58
Net Income	-$26.97M	$23.81M	$3.57B	$336.70M
7 Day Performance	-14.56%	4.01%	2.62%	3.29%
1 Month Performance	3.02%	1.98%	0.95%	1.72%
1 Year Performance	-48.98%	70.53%	37.04%	31.91%

CervoMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRVO CervoMed	3.7645 of 5 stars	$3.20 +1.7%	$22.60 +605.4%	-47.9%	$35.28M	N/A	N/A	4
PYXS Pyxis Oncology	2.6892 of 5 stars	$2.16 +1.4%	$6.83 +216.4%	+160.0%	$136.84M	$13.86M	N/A	60	News Coverage Gap Down
NRXP NRx Pharmaceuticals	2.617 of 5 stars	$3.76 -3.6%	$38.25 +917.3%	+17.0%	$136.23M	$1.23M	N/A	2
IFRX InflaRx	2.7785 of 5 stars	$1.88 -1.1%	$7.00 +272.3%	+182.2%	$135.91M	$30K	N/A	60	News Coverage Gap Down
VTVT vTv Therapeutics	2.4438 of 5 stars	$34.38 +1.4%	$53.00 +54.2%	+150.3%	$135.42M	$36.84M	N/A	9	News Coverage Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRVO) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CervoMed (CRVO) Competitors

CRVO vs. PYXS, NRXP, IFRX, VTVT, and OGI

How does CervoMed compare to Pyxis Oncology?

Summary

How does CervoMed compare to NRx Pharmaceuticals?

Summary

How does CervoMed compare to InflaRx?

Summary

How does CervoMed compare to vTv Therapeutics?

Summary

How does CervoMed compare to Organigram Global?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVO vs. The Competition

CervoMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CervoMed (CRVO) Competitors

CRVO vs. PYXS, NRXP, IFRX, VTVT, and OGI

How does CervoMed compare to Pyxis Oncology?

Do analysts rate PYXS or CRVO?

Which has preferable valuation & earnings, PYXS or CRVO?

Which has more volatility and risk, PYXS or CRVO?

Does the media refer more to PYXS or CRVO?

Do insiders and institutionals believe in PYXS or CRVO?

Is PYXS or CRVO more profitable?

Summary

How does CervoMed compare to NRx Pharmaceuticals?

Which has more volatility and risk, CRVO or NRXP?

Which has better earnings & valuation, CRVO or NRXP?

Does the media prefer CRVO or NRXP?

Do analysts recommend CRVO or NRXP?

Do insiders & institutionals believe in CRVO or NRXP?

Is CRVO or NRXP more profitable?

Summary

How does CervoMed compare to InflaRx?

Which has more volatility & risk, IFRX or CRVO?

Is IFRX or CRVO more profitable?

Do analysts recommend IFRX or CRVO?

Do insiders and institutionals have more ownership in IFRX or CRVO?

Does the media favor IFRX or CRVO?

Which has better valuation and earnings, IFRX or CRVO?

Summary

How does CervoMed compare to vTv Therapeutics?

Do analysts rate VTVT or CRVO?

Which has more volatility & risk, VTVT or CRVO?

Do insiders & institutionals have more ownership in VTVT or CRVO?

Does the media favor VTVT or CRVO?

Is VTVT or CRVO more profitable?

Which has higher earnings and valuation, VTVT or CRVO?

Summary

How does CervoMed compare to Organigram Global?

Do analysts rate OGI or CRVO?

Which has more volatility & risk, OGI or CRVO?

Do institutionals and insiders hold more shares of OGI or CRVO?

Does the media favor OGI or CRVO?

Is OGI or CRVO more profitable?

Which has higher valuation & earnings, OGI or CRVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVO vs. The Competition

CervoMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools